[News in oral antidiabetic therapy].
In this article two new peroral antidiabetics are introduced. The first is repaglinide, a prandial glucose regulator. The second is rosiglitazone, a member of the thiazolidinediones family, which improves the sensitivity of tissues to insulin and reduces insulin resistance.
Pospísilová
Y
Y
Interní hematoonkologická klinika FN Brno, pracovistĕ Bohunice.
D000284:Administration, Oral; D002219:Carbamates / Q000008:administration & dosage; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000077205:Pioglitazone; D010880:Piperidines / Q000008:administration & dosage; D000077154:Rosiglitazone; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology; D045162:Thiazolidinediones
D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C072379:repaglinide; C089946:2,4-thiazolidinedione; D000077205:Pioglitazone